Revotar reports positive Phase II results of bimosiamose in COPD
This article was originally published in Scrip
Executive Summary
Revotar Biopharmaceuticals of Germany has reported positive top-line results from a Phase II trial of inhaled bimosiamose, a pan-selectin antagonist for COPD. The company hopes to start a more extensive Phase II study by the start of 2012 with a view to conducting a Phase III trial in two years time, it told Scrip.